BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26068494)

  • 1. Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
    Kishi T; Matsuo Y; Ueki N; Iizuka Y; Nakamura A; Sakanaka K; Mizowaki T; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):619-26. PubMed ID: 26068494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
    Leung EY; Scott HR; McMillan DC
    J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model.
    Louie AV; Haasbeek CJ; Mokhles S; Rodrigues GB; Stephans KL; Lagerwaard FJ; Palma DA; Videtic GM; Warner A; Takkenberg JJ; Reddy CA; Maat AP; Woody NM; Slotman BJ; Senan S
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):82-90. PubMed ID: 26138912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
    Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study.
    Chen Z; Nonaka H; Onishi H; Nakatani E; Sato Y; Funayama S; Watanabe H; Komiyama T; Kuriyama K; Marino K; Aoki S; Araya M; Tominaga L; Saito R; Maehata Y; Oguri M; Saito M
    J Radiat Res; 2021 May; 62(3):457-464. PubMed ID: 33866376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S; Cho BC; Allibhai Z; Taremi M; Giuliani M; Le LW; Brade A; Sun A; Bezjak A; Hope AJ
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):532-8. PubMed ID: 24929163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
    Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer.
    Matsuo Y; Shibuya K; Nagata Y; Takayama K; Norihisa Y; Mizowaki T; Narabayashi M; Sakanaka K; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1104-11. PubMed ID: 20472343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
    Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis.
    Matsuo Y; Chen F; Hamaji M; Kawaguchi A; Ueki N; Nagata Y; Sonobe M; Morita S; Date H; Hiraoka M
    Eur J Cancer; 2014 Nov; 50(17):2932-8. PubMed ID: 25281527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer.
    Osugi J; Muto S; Matsumura Y; Higuchi M; Suzuki H; Gotoh M
    J Cancer Res Ther; 2016; 12(2):945-51. PubMed ID: 27461679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
    Grills IS; Mangona VS; Welsh R; Chmielewski G; McInerney E; Martin S; Wloch J; Ye H; Kestin LL
    J Clin Oncol; 2010 Feb; 28(6):928-35. PubMed ID: 20065181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy.
    Shi S; Ye L; Zhao Q; Hu Y; Huang Y; Chen G; Zeng Z; He J
    Jpn J Clin Oncol; 2019 Apr; 49(4):367-372. PubMed ID: 30715411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.
    Louie AV; Rodrigues G; Hannouf M; Zaric GS; Palma DA; Cao JQ; Yaremko BP; Malthaner R; Mocanu JD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):964-73. PubMed ID: 20932688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma.
    Tian R; Zhang F; Sun P; Wu J; Yan H; Wu AR; Zhang M; Jiang YL; Lu YH; Xu QY; Zhan XH; Zhang RX; Qian LT; He J
    Oncotarget; 2016 Oct; 7(41):67485-67494. PubMed ID: 27528228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
    Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
    Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.